What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The situation with the FDA and compounded GLP-1s (like semaglutide and tirzepatide) has been complex and has evolved rapidly. Here's a breakdown of what happened and who is currently operating legally:

What Happened with the FDA and Compounded GLP-1s?

1. Initial Shortages: When popular GLP-1 drugs like Ozempic, Wegovy (semaglutide), Mounjaro, and Zepbound (tirzepatide) first gained popularity, many experienced significant supply shortages. Under the Drug Quality and Security Act (DQSA), compounding pharmacies can prepare copies of commercially available drugs only if the FDA-approved version is on the official drug shortage list. This shortage initially opened the door for compounding.

2. FDA Concerns Emerge:

   • Unapproved Salt Forms: The FDA quickly became concerned that many compounding pharmacies were using semaglutide sodium or semaglutide acetate (salt forms) instead of the semaglutide base (the active ingredient in the FDA-approved drugs). The FDA explicitly stated that these salt forms are not the active ingredients in the approved drugs, and their safety and efficacy have not been established. This means they are unapproved new drugs when used in compounding.
   • Lack of Oversight & Quality Control: Compounded drugs do not undergo the same rigorous review for safety, effectiveness, and quality that FDA-approved drugs do. This raised concerns about purity, potency, sterility, and the potential for adverse events.
   • Misleading Marketing: Many compounding pharmacies and weight loss clinics marketed their compounded versions as being "the same" as the brand-name drugs, which the FDA views as misleading and dangerous.
   • Adverse Event Reports: The FDA and drug manufacturers received reports of adverse events, including severe nausea, vomiting, and other gastrointestinal issues, some potentially linked to compounded versions.

3. FDA Actions:

   • Warning Letters: The FDA issued warning letters to compounding pharmacies and online platforms engaged in illegal compounding or marketing of unapproved GLP-1s.
   • Public Statements & Alerts: They released numerous public statements and alerts, strongly warning consumers and healthcare providers against using compounded GLP-1 products unless very specific, narrow criteria were met.
   • Removal from Shortage List: Crucially, the FDA removed many of the GLP-1 products (or specific strengths) from its official drug shortage list. This action significantly restricts the legal ability of pharmacies to compound these drugs, even if they were using the correct base ingredient.

Who Is Still Operating Legally?

When it comes to GLP-1s for weight loss or diabetes, the answer regarding "legality" for compounding is very strict:

1. FDA-Approved Products (The Gold Standard):

   • Ozempic (semaglutide injection, for type 2 diabetes, often used off-label for weight loss)
   • Wegovy (semaglutide injection, specifically FDA-approved for chronic weight management)
   • Mounjaro (tirzepatide injection, for type 2 diabetes, often used off-label for weight loss)
   • Zepbound (tirzepatide injection, specifically FDA-approved for chronic weight management)

   These are dispensed by licensed pharmacies (like CVS Pharmacy, Walgreens, Rite Aid, Kroger Pharmacy, Costco Pharmacy, and many independent pharmacies) with a valid prescription from a licensed healthcare provider. This is the safest and most recommended route.

2. Legitimate Compounding Pharmacies (Under VERY Strict Conditions): A compounding pharmacy (either a 503A traditional pharmacy or a 503B outsourcing facility) can only legally compound a GLP-1 drug if all of the following conditions are met:

   • Genuine Shortage: The specific FDA-approved drug and strength is currently listed on the FDA's official drug shortage list. Many GLP-1s are no longer on this list, or only very specific formulations are.
   • Use of Base API: The pharmacy must use the active pharmaceutical ingredient (API) that is the base compound (e.g., semaglutide base, tirzepatide base), not unapproved salt forms like semaglutide sodium or semaglutide acetate.
   • Individual Patient Need: It must be compounded for an individual patient based on a valid prescription from a licensed physician, addressing a specific medical need (e.g., allergy to a non-active ingredient in the commercial product). It cannot be compounded in anticipation of future prescriptions or for general sale.
   • State Board of Pharmacy Regulation: The compounding pharmacy must be properly licensed and regulated by its state board of pharmacy.

   Important Note: Given that most GLP-1 drugs are not currently on the FDA's official shortage list, and the FDA has specifically warned against the use of salt forms, the instances where compounding of GLP-1s is truly legal are extremely rare.

Consumer Advice:

• Prioritize FDA-Approved: Always seek out the FDA-approved brand-name medications dispensed by a licensed pharmacy with a prescription from a healthcare provider you trust.
• Ask Questions: If offered a compounded GLP-1, ask your provider and the pharmacy:
  • Is the FDA-approved version currently on the official shortage list?
  • Are you using the base active pharmaceutical ingredient (e.g., semaglutide base), or a salt form (like semaglutide sodium/acetate)?
  • What are your quality control and sterility testing procedures?
• Be Wary of Red Flags: Be skeptical of unusually low prices, claims that a compounded drug is "exactly the same" as a brand-name drug, or offers to provide GLP-1s without a thorough medical evaluation and prescription.

In summary, the FDA has largely clamped down on compounded GLP-1s due to concerns about unapproved ingredients, lack of oversight, and safety. The safest and most legal route remains obtaining an FDA-approved prescription for drugs like Ozempic, Wegovy, Mounjaro, or Zepbound from a legitimate healthcare provider and filling it at a licensed pharmacy.